Dopamine D1 receptors of the calf parathyroid gland

Identification and characterization

H. B. Niznik, Evan Fogel, C. J. Chen, D. Congo, E. M. Brown, P. Seeman

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The dopamine D1 receptor was identified in the calf parathyroid gland. The binding of the selective D1 receptor antagonist [3H]SCH-23390 to membranes of calf parathyroid was specific, reversible, and saturable with a dissociation constant of ~200 pM and a receptor density of 30 fmol/mg of protein. Dopaminergic agonists and antagonists inhibited [3H]SCH-23390 binding in a concentration-dependent and stereoselective manner with an appropriate pharmacological specificity for D1 dopamine receptors. Moreover, potent dopaminergic agonists recognized two affinity forms of the receptor, one displaying high affinity for agonists, termed D1(High), and one with low affinity, D1(Low). The addition of the nonhydrolyzable guanine nucleotide guanyl 5'-yl-imidodiphosphate caused the complete transition of the agonist high affinity form (D1(High)) of the receptor to one displaying only low affinity for agonists (D1(Low)). Sodium ions, however, caused a ~5-fold decrease in the affinity of agonists at both D1(High) and D1(Low). Virtually identical results were obtained on D1 receptor preparations of neural origin. The D1 receptor identified here appears to be the one responsible for the physiological effects on the parathyroid gland, because dopamine-stimulated cAMP accumulation is stereoselectively blocked by the D1 receptor antagonist SCH-23390 in dispersed cells of the parathyroid gland. Moreover, a series of nine dopaminergic antagonists and agonists shows an excellent correlation between their potency in [3H]SCH-23390 binding assays and their corresponding effects on cAMP accumulation. In the case of agonists, K(a) for activation of cAMP accumulation agrees most closely with the agonist low affinity site in binding experiments. Specific [3H]spiperone binding to D2 dopamine receptors was not detected in this tissue and as such, the calf-parathyroid gland provides a model system in which to study the molecular characteristics of dopamine D1 receptor-mediated events.

Original languageEnglish (US)
Pages (from-to)29-36
Number of pages8
JournalMolecular Pharmacology
Volume34
Issue number1
StatePublished - 1988
Externally publishedYes

Fingerprint

Dopamine D1 Receptors
Parathyroid Glands
Dopamine Agonists
Dopamine Antagonists
Guanylyl Imidodiphosphate
Spiperone
Guanine Nucleotides
Dopamine D2 Receptors
Sensory Receptor Cells
Dopamine
Sodium
Binding Sites
Pharmacology
Ions
Membranes
SCH 23390
Proteins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Niznik, H. B., Fogel, E., Chen, C. J., Congo, D., Brown, E. M., & Seeman, P. (1988). Dopamine D1 receptors of the calf parathyroid gland: Identification and characterization. Molecular Pharmacology, 34(1), 29-36.

Dopamine D1 receptors of the calf parathyroid gland : Identification and characterization. / Niznik, H. B.; Fogel, Evan; Chen, C. J.; Congo, D.; Brown, E. M.; Seeman, P.

In: Molecular Pharmacology, Vol. 34, No. 1, 1988, p. 29-36.

Research output: Contribution to journalArticle

Niznik, HB, Fogel, E, Chen, CJ, Congo, D, Brown, EM & Seeman, P 1988, 'Dopamine D1 receptors of the calf parathyroid gland: Identification and characterization', Molecular Pharmacology, vol. 34, no. 1, pp. 29-36.
Niznik, H. B. ; Fogel, Evan ; Chen, C. J. ; Congo, D. ; Brown, E. M. ; Seeman, P. / Dopamine D1 receptors of the calf parathyroid gland : Identification and characterization. In: Molecular Pharmacology. 1988 ; Vol. 34, No. 1. pp. 29-36.
@article{2dad5058dc4149378778c2553f85c210,
title = "Dopamine D1 receptors of the calf parathyroid gland: Identification and characterization",
abstract = "The dopamine D1 receptor was identified in the calf parathyroid gland. The binding of the selective D1 receptor antagonist [3H]SCH-23390 to membranes of calf parathyroid was specific, reversible, and saturable with a dissociation constant of ~200 pM and a receptor density of 30 fmol/mg of protein. Dopaminergic agonists and antagonists inhibited [3H]SCH-23390 binding in a concentration-dependent and stereoselective manner with an appropriate pharmacological specificity for D1 dopamine receptors. Moreover, potent dopaminergic agonists recognized two affinity forms of the receptor, one displaying high affinity for agonists, termed D1(High), and one with low affinity, D1(Low). The addition of the nonhydrolyzable guanine nucleotide guanyl 5'-yl-imidodiphosphate caused the complete transition of the agonist high affinity form (D1(High)) of the receptor to one displaying only low affinity for agonists (D1(Low)). Sodium ions, however, caused a ~5-fold decrease in the affinity of agonists at both D1(High) and D1(Low). Virtually identical results were obtained on D1 receptor preparations of neural origin. The D1 receptor identified here appears to be the one responsible for the physiological effects on the parathyroid gland, because dopamine-stimulated cAMP accumulation is stereoselectively blocked by the D1 receptor antagonist SCH-23390 in dispersed cells of the parathyroid gland. Moreover, a series of nine dopaminergic antagonists and agonists shows an excellent correlation between their potency in [3H]SCH-23390 binding assays and their corresponding effects on cAMP accumulation. In the case of agonists, K(a) for activation of cAMP accumulation agrees most closely with the agonist low affinity site in binding experiments. Specific [3H]spiperone binding to D2 dopamine receptors was not detected in this tissue and as such, the calf-parathyroid gland provides a model system in which to study the molecular characteristics of dopamine D1 receptor-mediated events.",
author = "Niznik, {H. B.} and Evan Fogel and Chen, {C. J.} and D. Congo and Brown, {E. M.} and P. Seeman",
year = "1988",
language = "English (US)",
volume = "34",
pages = "29--36",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Dopamine D1 receptors of the calf parathyroid gland

T2 - Identification and characterization

AU - Niznik, H. B.

AU - Fogel, Evan

AU - Chen, C. J.

AU - Congo, D.

AU - Brown, E. M.

AU - Seeman, P.

PY - 1988

Y1 - 1988

N2 - The dopamine D1 receptor was identified in the calf parathyroid gland. The binding of the selective D1 receptor antagonist [3H]SCH-23390 to membranes of calf parathyroid was specific, reversible, and saturable with a dissociation constant of ~200 pM and a receptor density of 30 fmol/mg of protein. Dopaminergic agonists and antagonists inhibited [3H]SCH-23390 binding in a concentration-dependent and stereoselective manner with an appropriate pharmacological specificity for D1 dopamine receptors. Moreover, potent dopaminergic agonists recognized two affinity forms of the receptor, one displaying high affinity for agonists, termed D1(High), and one with low affinity, D1(Low). The addition of the nonhydrolyzable guanine nucleotide guanyl 5'-yl-imidodiphosphate caused the complete transition of the agonist high affinity form (D1(High)) of the receptor to one displaying only low affinity for agonists (D1(Low)). Sodium ions, however, caused a ~5-fold decrease in the affinity of agonists at both D1(High) and D1(Low). Virtually identical results were obtained on D1 receptor preparations of neural origin. The D1 receptor identified here appears to be the one responsible for the physiological effects on the parathyroid gland, because dopamine-stimulated cAMP accumulation is stereoselectively blocked by the D1 receptor antagonist SCH-23390 in dispersed cells of the parathyroid gland. Moreover, a series of nine dopaminergic antagonists and agonists shows an excellent correlation between their potency in [3H]SCH-23390 binding assays and their corresponding effects on cAMP accumulation. In the case of agonists, K(a) for activation of cAMP accumulation agrees most closely with the agonist low affinity site in binding experiments. Specific [3H]spiperone binding to D2 dopamine receptors was not detected in this tissue and as such, the calf-parathyroid gland provides a model system in which to study the molecular characteristics of dopamine D1 receptor-mediated events.

AB - The dopamine D1 receptor was identified in the calf parathyroid gland. The binding of the selective D1 receptor antagonist [3H]SCH-23390 to membranes of calf parathyroid was specific, reversible, and saturable with a dissociation constant of ~200 pM and a receptor density of 30 fmol/mg of protein. Dopaminergic agonists and antagonists inhibited [3H]SCH-23390 binding in a concentration-dependent and stereoselective manner with an appropriate pharmacological specificity for D1 dopamine receptors. Moreover, potent dopaminergic agonists recognized two affinity forms of the receptor, one displaying high affinity for agonists, termed D1(High), and one with low affinity, D1(Low). The addition of the nonhydrolyzable guanine nucleotide guanyl 5'-yl-imidodiphosphate caused the complete transition of the agonist high affinity form (D1(High)) of the receptor to one displaying only low affinity for agonists (D1(Low)). Sodium ions, however, caused a ~5-fold decrease in the affinity of agonists at both D1(High) and D1(Low). Virtually identical results were obtained on D1 receptor preparations of neural origin. The D1 receptor identified here appears to be the one responsible for the physiological effects on the parathyroid gland, because dopamine-stimulated cAMP accumulation is stereoselectively blocked by the D1 receptor antagonist SCH-23390 in dispersed cells of the parathyroid gland. Moreover, a series of nine dopaminergic antagonists and agonists shows an excellent correlation between their potency in [3H]SCH-23390 binding assays and their corresponding effects on cAMP accumulation. In the case of agonists, K(a) for activation of cAMP accumulation agrees most closely with the agonist low affinity site in binding experiments. Specific [3H]spiperone binding to D2 dopamine receptors was not detected in this tissue and as such, the calf-parathyroid gland provides a model system in which to study the molecular characteristics of dopamine D1 receptor-mediated events.

UR - http://www.scopus.com/inward/record.url?scp=0023820537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023820537&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 29

EP - 36

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 1

ER -